| Objective To investigate the effect of isopsoralen combined with zinc treatment on bone strength and bone mass in type 1 diabetic rats, and explore possible mechanisms. Methods In this study, type 1 diabetic rat models were established by streptozotocin injection (60mg / kg); subsequently, type 1 diabetic rats were randomly divided into type 1 diabetic group (Con), zinc treatment group (Zn), and tonic The osteolipin group (Bgz) and zinc combined with isopsoralen group (Zn + Bgz), 10 in each group; Among them, rats in the isopsoralen group and the zinc treatment group and the combination treatment group received zinc sulfate, Psoralen and the combination of the two were treated for 12 weeks; after treatment, Micro-CT, HE stained sections, bone biomechanical detection and Western blot were used to observe the treatment effect and possible mechanism. Results After 12 weeks of treatment, compared with the Zn group and the Bgz group, the number of trabeculae and bone density in the Zn + Bgz group were significantly improved. BMD, TV / BV, Tb.N, Tb.Th, and Tb.Sp in the Zn + Bgz group were significantly improved compared with the Zn and Bgz groups (P <0.05). At 12 weeks of treatment, the maximum load, stiffness, and maximum power consumption in the Zn + Bgz group were significantly increased compared with the Zn and Bgz groups (P <0.05), which was statistically significant (P <0.05). Compared with the Zn group and the Bgz group, the Wnt / β-catenin signaling pathway in the Zn + Bgz group was activated, and the levels of Wnt 1, Wnt 5a, p-GSK-3β, GSK-3β, and β-catenin were significantly increased (P <0.05). Conclusion Both isopsoralen and zinc can activate the bone protection effect of type 1 diabetic rats through Wnt / β-catenin signaling pathway activation, and the combined treatment is better. |